Results 161 to 170 of about 93,221 (259)

A Case of IDH-Mutant Astrocytoma Harboring an IDH2 R172_H173delinsSN Variant. [PDF]

Neuropathology
ABSTRACT IDH‐mutant gliomas most commonly harbor the canonical IDH1 p.R132H mutation, followed by less common mutations involving IDH1 p.R132 or IDH2 p.R172 codons. We present a case of a 32‐year‐old male found to have a left temporal brain tumor with regional enhancement on brain MRI, for which he underwent resection.
Auen T, Chen J, Shonka N, Cathcart S.
europepmc   +2 more sources

Targeting WTAP/ROR1/WNT5A‐Mediated Crosstalk Between Glioma Stem Cells and Macrophages to Normalize Tumor Vasculature and Enhance Chemotherapy

Advanced Science, Volume 13, Issue 21, 13 April 2026.
In hypoxic microenvironment, WNT5A is predominantly secreted by tumor‐associated macrophages. Hypoxia‐induced WTAP mediates ROR1 stability by m6A modifications in a HuR‐dependent manner in Glioma stem cells (GSCs). WNT5A activates the WNT pathway via ROR1 binding on GSCs, driving glioma‐derived endothelial cells (GDECs) differentiation.
Xiaoyong Chen, Bo Pang, Yun Liu, Jiangwei Wang, Lanhui Zheng, Yuzhou Chang, Yingxuan Sun, Haoyuan Sun, Huiyuan Chen, Jiawei Cai, Zanyi Wu, Qing Chang, Yongzhi Wang, Dezhi Kang, Tao Jiang, Ruichao Chai   +15 more
wiley   +1 more source

Design, Synthesis and Evaluation of Anticancer Potential of Novel Pyrrolopyrazines Against Glioblastoma: Mechanistic Details and In Vivo Safety Analysis

Archiv der Pharmazie, Volume 359, Issue 4, April 2026.
Propargyl–pyrrole cyclization yielded 12 pyrrolo[1,2‐a]pyrazine derivatives, with naphthyl‐substituted 3g showing potent antiproliferative activity against U87MG glioblastoma. Compound 3g induced multiple cell death pathways without significant renal or hepatic toxicity, highlighting its promise as a glioblastoma therapeutic candidate.
Ayşe Usta, Burak Kuzu, Meltem Tan‐Uygun, Veysel Yüksek, M. Edip Akyol, Nurettin Menges   +5 more
wiley   +1 more source

Efficacy Assessment of Supramarginal Resection Versus Gross Total Resection in Glioblastoma: A Systematic Literature Review and Meta‐Analysis

Brain and Behavior, Volume 16, Issue 4, April 2026.
Glioblastoma (GBM) carries a poor prognosis (median survival 15–18 months). Supramarginal resection (SMR) extends beyond contrast enhancement into T2/FLAIR to remove infiltrative tumor. In a meta‐analysis of 12 studies (6524 patients), SMR was associated with improved overall and progression‐free survival versus gross‐total resection (GTR) without ...
Dipak Chaulagain, Volodymyr Smolanka, Andriy Smolanka, Kashif Qureshi, Kivanc Yangi, Oleg Devnyak, Bipin Chaurasia   +6 more
wiley   +1 more source

Glioblastoma and PARP inhibitors: the importance of patient selection to maximize therapeutic benefits. A critical review. [PDF]

Front Oncol
Dima G, Di Nunno V, Aprile M, Gatto L, Tosoni A, Argento CM, Margotti M, Bartolini S, Franceschi E.   +8 more
europepmc   +1 more source

Nationwide Incidence, Treatment Pattern, and Prognosis of Primary CNS Lymphoma in Taiwan, 2012–2020: A Retrospective Cohort Study

Cancer Medicine, Volume 15, Issue 4, April 2026.
Using data from the Taiwan Cancer Registry, the Taiwan National Health Insurance Research Database, and the Taiwan National Death Registry, this nationwide real‐world study examined the epidemiology, treatment patterns, prognosis, medical costs, and adverse events associated with primary central nervous system lymphoma (PCNSL) in Taiwan over a nine ...
Fei‐Yuan Hsiao, Hung‐Yu Lin, Ho‐Min Chen, Wan‐Hsuan Hsu, Bor‐Sheng Ko   +4 more
wiley   +1 more source

Regrowth Patterns in Glioblastoma—Survival and Predictors

Cancer Medicine, Volume 15, Issue 4, April 2026.
Multiple glioblastoma relapse patterns were associated with patients' progression‐free and overall survival, even when other known prognostic factors were taken into account. Treatment with Tumor Treating Fields was associated with prolonged progression‐free survival and predictive for a higher frequency of non‐local recurrence patterns after subtotal ...
Jonas A. Feldheim, Jana Grieger, Teresa Schmidt, Christoph Oster, Julia J. Feldheim, Pia Wepner, Elke Hattingen, Carsten Hagemann, Ulrich Sure, Ulrich Herrlinger, Martin Stuschke, Björn Scheffler, Cornelius Deuschl, Christoph Kleinschnitz, Lazaros Lazaridis, Sied Kebir, Niklas Schäfer, Martin Glas   +17 more
wiley   +1 more source

Phase I/II Study of the CDK2/9 Inhibitor Fadraciclib in Combination with Chemotherapy in Children with Advanced Malignancies: Arm K of the AcSé-ESMART Trial. [PDF]

Target Oncol
Rubio-San-Simón A, Marshall LV, Karamouza E, André N, Abbou S, Rubino J, Nebchi S, Aerts I, Thebaud E, Brisset C, Ducassou S, Le Teuff G, Geoerger B.   +12 more
europepmc   +1 more source

Progression‐Free Survival 2 as a Potential Surrogate for Overall Survival in Glioblastoma: Insights From a Spanish Multicentric Cohort

Cancer Medicine, Volume 15, Issue 4, April 2026.
Overall, PFS2 correlated more strongly with OS than PFS (0.83 vs. 0.69). PFS2 outperformed PFS in patients with targetable alterations and in those without. Our findings support using PFS2 as a candidate surrogate endpoint in glioblastoma trials. Implementing PFS2 balances trial feasibility with clinical relevance of outcomes.
Jesús Yaringaño, Oriol Mirallas, Víctor Navarro, Diego Gómez‐Puerto, Gabriel Velilla, María Ángeles Vaz, Teresa Gorria, Álvaro Martínez‐Monino, Ainhoa Hernández, María Aguado, Antonio Di Muzio, Daniel López Valbuena, Fiorella Ruiz‐Pace, Macarena González, María Martínez‐García, Guillermo Villacampa, Carmen Balaña, Joan Carles, Rodrigo Dienstmann, Estela Pineda, Juan Manuel Sepúlveda, María Vieito   +21 more
wiley   +1 more source

The Time-Dependent Effects of Temozolomide on Autophagy Gene Expression in Glioblastoma Cells. [PDF]

Biomedicines
Kiraz İ, Aydın VK, Kurt Ö, Coşkun ME, Lengerova G, Bozhkova M, Petrov S, Köseler A.   +7 more
europepmc   +1 more source